Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $1.3 million.

  • Innate Pharma's Other Non-Current Liabilities rose 21001.62% to $1.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year increase of 21001.62%. This contributed to the annual value of $296560.7 for FY2024, which is 5453.45% down from last year.
  • Innate Pharma's Other Non-Current Liabilities amounted to $1.3 million in Q2 2025, which was up 21001.62% from $292795.1 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Other Non-Current Liabilities registered a high of $6.8 million during Q2 2021, and its lowest value of $202009.0 during Q4 2022.
  • For the 5-year period, Innate Pharma's Other Non-Current Liabilities averaged around $1.4 million, with its median value being $648791.8 (2023).
  • Per our database at Business Quant, Innate Pharma's Other Non-Current Liabilities tumbled by 9741.54% in 2021 and then skyrocketed by 22116.98% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Other Non-Current Liabilities stood at $289424.7 in 2021, then crashed by 30.2% to $202009.0 in 2022, then surged by 221.17% to $648791.8 in 2023, then plummeted by 54.87% to $292795.1 in 2024, then soared by 327.58% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q2 2025, $292795.1 for Q4 2024, and $403832.9 during Q2 2024.